Rozbor firmy
Thermo Fisher Scientific (TMO): picks-and-shovels in healthcare
Key takeaways
- Thermo Fisher sells tools and consumables to scientists, pharmaceutical companies and hospitals — a picks-and-shovels model in life sciences.
- The moat is formed by the breadth of the portfolio, distributor network and customer switching costs in regulated industries.
- The company benefits from secular growth in spending on science, genomics and biologic drug manufacturing.
- Risk is the normalisation of post-COVID product demand and a slowdown in pharmaceutical customer spending.
- As a constituent of healthcare ETFs (XDWH), TMO is a natural part of a diversified sector approach.
Thermo Fisher Scientific (TMO) is not a pharmaceutical company — it is a supplier of tools, instruments and consumables for everyone who does science or manufactures drugs. An investor thus gains exposure not to a single drug but to the entire research and manufacturing ecosystem in life sciences.
The picks-and-shovels logic
The gold-rush analogy holds here too: rather than betting on which company finds the "golden drug", TMO sells the picks and shovels — centrifuges, sequencers, reagents, chromatography columns, bioreactors for biologics manufacturing. Customers are pharmaceutical companies, biotechs, hospitals, academic institutions and government agencies.
Economic moat
TMO's moat rests on the breadth of its portfolio (a single supplier for hundreds of products reduces customer switching costs), regulatory validation of instruments (in a regulated manufacturing environment, changing supplier is expensive and time-consuming) and a global network of service engineers.
Opportunities and risks
- Secular trends: genomics, personalised medicine and mRNA vaccine manufacturing increase demand for TMO instruments.
- Post-pandemic normalisation: COVID testing and vaccine manufacturing inflated revenue in 2020–2022; the return to normality was painful — income from those sources declined.
- Customer concentration: large pharmaceutical companies, when cutting R&D, directly affect demand for TMO instruments.
- Acquisitions: TMO also grows through acquisitions that bring synergies but also integration risk and debt.
ETF and investment approach
TMO is a typical constituent of healthcare sector ETFs. Through XDWH you get TMO alongside pharmaceutical and insurance names. If the picks-and-shovels logic interests you in other sectors as well, read through the company analyses or the overall ETF overview.
FAQ
What is the picks-and-shovels strategy in investing?
Rather than betting on the company that will "win the race" (a new drug, a new technology), you buy the supplier of tools for the entire industry. TMO supplies instruments to all pharmaceutical companies — it profits whoever wins.
Why did TMO revenue fall after COVID?
COVID generated extraordinary demand for diagnostics, testing and vaccine manufacturing. Once the pandemic subsided, demand normalised. Investors who did not account for this cyclicality were surprised by the revenue decline.
Is TMO included in healthcare ETFs?
Yes — TMO is a standard constituent of sector funds tracking healthcare or life sciences indices. In an ETF such as XDWH you get it automatically alongside other healthcare names.